Compare PRCH & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCH | TSHA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2019 | 2020 |
| Metric | PRCH | TSHA |
|---|---|---|
| Price | $17.06 | $5.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $18.63 | $11.63 |
| AVG Volume (30 Days) | 1.8M | ★ 2.6M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | 5.56 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $482,414,000.00 | $9,773,000.00 |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | $17.05 | $1,152.42 |
| P/E Ratio | $1,709.00 | ★ N/A |
| Revenue Growth | 10.18 | ★ 17.28 |
| 52 Week Low | $6.36 | $2.72 |
| 52 Week High | $19.44 | $7.30 |
| Indicator | PRCH | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 65.65 | 48.53 |
| Support Level | $9.08 | $5.28 |
| Resistance Level | N/A | $6.76 |
| Average True Range (ATR) | 0.73 | 0.33 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 83.97 | 32.30 |
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.